Rivaroxaban

Generic Name
Rivaroxaban
Brand Names
Xarelto, Rivaroxaban Accord, Rivaroxaban Viatris (previously Rivaroxaban Mylan)
Drug Type
Small Molecule
Chemical Formula
C19H18ClN3O5S
CAS Number
366789-02-8
Unique Ingredient Identifier
9NDF7JZ4M3
Background

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.

Indication

Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).

Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.

Associated Conditions
Cardiovascular Mortality, Deep Vein Thrombosis, Deep vein thrombosis recurrent, Major Adverse Cardiovascular Events, Myocardial Infarction, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Recurrent Venous Thromboembolism, Stroke, Systemic Embolism, Thrombosis, Venous Thromboembolism
Associated Therapies
-

Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD

First Posted Date
2017-09-08
Last Posted Date
2017-09-08
Lead Sponsor
Huashan Hospital
Target Recruit Count
438
Registration Number
NCT03277001
Locations
🇨🇳

Huashan hospital,Fudan university, Shanghai, Shanghai, China

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Phase 4
Recruiting
Conditions
Interventions
First Posted Date
2017-08-30
Last Posted Date
2024-10-15
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
2760
Registration Number
NCT03266783
Locations
🇮🇪

The Royal College of Surgeons in Ireland/Mater Misericordiae University Hospital, Dublin, Ireland

🇨🇦

St. Mary's Hospital, Montreal, Quebec, Canada

🇨🇦

Alberta Health Sciences, Edmonton, Alberta, Canada

and more 16 locations

Medical Need of OAC Reversal

First Posted Date
2017-08-18
Last Posted Date
2019-03-04
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
53969
Registration Number
NCT03254147
Locations
🇯🇵

Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV

First Posted Date
2017-06-28
Last Posted Date
2017-06-28
Lead Sponsor
Zagazig University
Target Recruit Count
40
Registration Number
NCT03201367

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

Phase 3
Conditions
Interventions
First Posted Date
2017-06-20
Last Posted Date
2017-10-13
Lead Sponsor
Sherief Abd-Elsalam
Target Recruit Count
40
Registration Number
NCT03193502
Locations
🇪🇬

Tropical medicine dept.-Tanta university hospital, Cairo, Egypt

Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants

First Posted Date
2017-06-08
Last Posted Date
2022-06-15
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
60
Registration Number
NCT03181386
Locations
🇧🇷

Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Study of Rivaroxaban for CeREbral Venous Thrombosis

First Posted Date
2017-06-07
Last Posted Date
2022-12-14
Lead Sponsor
University of British Columbia
Target Recruit Count
55
Registration Number
NCT03178864
Locations
🇨🇦

Kelowna General Hospital, Kelowna, British Columbia, Canada

🇨🇦

Hamilton Health Sciences Centre, Hamilton, Ontario, Canada

🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 8 locations

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

Phase 2
Completed
Conditions
Interventions
First Posted Date
2017-06-01
Last Posted Date
2020-09-09
Lead Sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Target Recruit Count
69
Registration Number
NCT03172910
Locations
🇺🇸

Frontage Clinical Services Inc., Secaucus, New Jersey, United States

Start or STop Anticoagulants Randomised Trial (SoSTART)

First Posted Date
2017-05-15
Last Posted Date
2022-04-08
Lead Sponsor
University of Edinburgh
Target Recruit Count
203
Registration Number
NCT03153150
Locations
🇬🇧

Frimley Park Hospital, Frimley, United Kingdom

🇬🇧

Gloucestershire Royal Hospital, Gloucester, United Kingdom

🇬🇧

Pinderfields Hospital, Wakefield, United Kingdom

and more 64 locations
© Copyright 2024. All Rights Reserved by MedPath